Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
about
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyRenal cell carcinoma.Quality of life and targeted treatment for metastatic renal cell carcinoma.General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitorsFuture perspectives for mTOR inhibitors in renal cell cancer treatment.Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.The Role of Everolimus in Renal Cell Carcinoma.
P2860
Q26766240-CE794983-4C9C-4591-8C42-447F27F5285AQ28079861-A560F219-AC98-4F99-A941-4D26CE1D45CFQ30235364-BB31F746-185A-4469-B131-C58B892CDE58Q35584690-61FDE3F1-CB5F-4100-A460-EC6D430680A7Q36315466-7AA9E4DE-47E8-4253-989E-271B3418607EQ36625333-251562CC-503A-415B-A82D-D7770E982EB3Q36889650-153C240B-C0AD-4672-A097-CC0618ABB7F9Q36959193-C6FCD1DF-DE4A-4CCE-A942-C331DF1BD304Q38372445-9A3D5658-9CFB-47EB-84DF-5B546517BE44Q48067491-1B294FA2-F0B0-4690-9A04-11DB4BDD5DFFQ52979097-727EA1D2-C19B-4525-8A35-7AEC26FFC03A
P2860
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@ast
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@en
type
label
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@ast
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@en
prefLabel
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@ast
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@en
P2093
P2860
P50
P921
P1433
P1476
Patient-reported outcomes in a ...... sine kinase inhibitor therapy.
@en
P2093
Andrea Kay
Jeanfrancois Baladi
Jennifer L Beaumont
Norbert Hollaender
Tomas Haas
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0299
P577
2011-04-01T00:00:00Z